LB252

Nebraska LB252 aims to prevent insurance and Medicaid from disadvantaging non-opioid pain management drugs.

Nebraska LB252 seeks to ensure that non-opioid drugs for pain management are not disadvantaged compared to opioid drugs in terms of insurance and Medicaid coverage. The bill prohibits more restrictive coverage criteria, utilization controls, and cost-sharing requirements for non-opioid drugs. It applies to both commercial insurance and Medicaid, ensuring that non-opioid drugs are not placed on less favorable tiers or subjected to more stringent prior authorization or step therapy requirements. The bill emphasizes equal access to pain management treatments for patients and prescribers.